Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI

Journal of Geriatric Cardiology

Volumn 9, Issue 3, 2012, Pages 252-257

  Ma, Cong ^a   Cao, Jian ^a   Lu, Xue Chun ^a   Guo, Xin Hong ^a   Gao, Yan ^a   Liu, Xian Feng ^a   Fan, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Angiotensin type 2 receptor; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; BRAIN INFARCTION; CROSS-SECTIONAL STUDY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

EID: 84873714064     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1263.2011.12031     Document Type: Article

References (30)

1. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. (Pubitemid 38781102)
2. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776. (Pubitemid 37093917)
3. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
4. Tsutsui H, Matsushima S, Kinugawa S, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 2007; 30: 439-449. (Pubitemid 46958894)
5. Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J Renin Angiotensin Aldosterone Syst 2005; 6: 43-48. (Pubitemid 40796848)
6. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
8. Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006; 24: S115-S121. (Pubitemid 44339435)
9. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
10. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival study (ELITE II). Lancet 2000; 355: 1582-1587. (Pubitemid 30240502)
11. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. OPTIMAAL randomized trial. Optimal Trial in Myocardial infarction with Angiotensin II antagonist Losartan. Lancet 2002; 360: 752-760. (Pubitemid 35247704)
12. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372: 547-553.
13. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174- 1183.
14. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449. (Pubitemid 24102039)
15. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin- aldosterone system. Nat Rev Drug Discov 2002; 1: 621-636. (Pubitemid 37368827)
16. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8-13. (Pubitemid 38056012)
17. Mogi M, Iwai M, Horiuchi M. Emerging concept of adipogenesis regulation by the renin-angiotensin system. Hypertension 2006; 48: 1020-1022. (Pubitemid 44772700)
18. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35:1074-1077. (Pubitemid 30327260)
19. Volpe M, Tocci G, Savoia C. Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents'. Eur Heart J 2006; 27: 1506-1507. (Pubitemid 43998088)
20. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996; 97: 1978-1982.
21. Siragy HM, Jaffa AA, Margolius HS, et al. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271: R1090-R1095.
22. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-269. (Pubitemid 27349072)
23. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97. (Pubitemid 46127306)
24. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005; 45: 840-844. (Pubitemid 40628923)
25. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201. (Pubitemid 40979958)
26. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001; 158: 1743-1756. (Pubitemid 32422939)
27. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108: 391-394. (Pubitemid 36935529)
28. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or preventionof microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364: 907-917.
29. Takahashi W, Tsukamoto Y, Ohnuki T, et al. Is mild renal dysfunction a risk factor for carotid atherosclerosis in apparently healthy adults? Intern Med 2011; 50: 2285-2289.
30. Yiu KH, de Graaf FR, Schuijf JD, et al. Prognostic value of renal dysfunction for the prediction of outcome versus results of computed tomographic coronary angiography. Am J Cardiol 2011; 108: 968-972.